A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCLGraham P. Collins, Dima El‐Sharkawi, Daniel Chan et al.|Blood|2023Cited by 9
777 Initial clinical characterization of novel proximal biomarkers for NX-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced malignanciesSarah Whelan, Janine Powers, Ganesh Cherala et al.|Regular and Young Investigator Award Abstracts|2022Cited by 2
850 Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignanciesRuth Plummer, Nagy Habib, Anthony B. El-Khoueiry et al.|Regular and Young Investigator Award Abstracts|2022Cited by 1